?Remdesivir (CAS 1809249-37-3)?
?? ?ChemicalBook Product Introduction?

?? ?Product Overview?

?Remdesivir? (GS-5734) is a ?broad-spectrum antiviral nucleotide analog? with the molecular formula ?C27H35N6O8P?. As a prodrug of GS-441524, it inhibits ?RNA-dependent RNA polymerase (RdRp)?, effectively blocking viral replication by incorporating into viral RNA chains. Primarily used to treat ?COVID-19?, it also demonstrates activity against ?Ebola?, ?MERS-CoV?, and ?SARS-CoV?. Supplied as a white crystalline powder with ≥99% purity (HPLC verified), it is stable under recommended storage conditions (?-20°C?).

?Google Keywords?: Remdesivir CAS 1809249-37-3, GS-5734 Supplier, COVID-19 Antiviral API, High-Purity RdRp Inhibitor

? ?Key Advantages?

       ?? ?High Purity & Stability?

• ?≥99% purity? (HPLC/UV verified) | Long-term stability at ?-20°C?.
  ?? ?Potent Antiviral Activity?

• ?EC50 = 30 nM? against murine hepatitis virus (MHV) | ?74 nM EC50? for SARS-CoV and MERS-CoV in HAE cells.
  ?? ?Global Compliance?

• Produced in ?GMP-certified facilities? | Complies with ?EP/USP/CP? standards.

?? ?Application Fields?

• ?COVID-19 Treatment?: Approved for emergency use in severe cases.

• ?Ebola & MERS Research?: Clinical trials for filovirus infections.

• ?Antiviral Development?: Key component in RNA virus therapeutic research.

?? ?Quality Certifications?

• ?Testing Methods?: HPLC, NMR, MS, and microbial limit testing.

• ?Certifications?: ?ISO 9001?, ?GMP?, and ?FDA-aligned protocols?.

?? ?Market Trends?

The ?global antiviral drug market? is projected to grow at ?6.5% CAGR (2025-2030)?, driven by persistent COVID-19 variants and emerging RNA virus threats. Remdesivir remains a frontline therapeutic, with Asia-Pacific regions leading production and R&D.